Format

Send to

Choose Destination
Neurology. 2003 Feb 11;60(3):381-9.

Slowing Parkinson's disease progression: recent dopamine agonist trials.

Author information

1
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. eahlskog@mayo.edu

Abstract

In recent clinical trials, chronic treatment of patients with PD with pramipexole or ropinirole was associated with a slower decline of imaged striatal dopaminergic signal, compared to levodopa monotherapy. Although this could reflect slowed progression of PD, equally plausible is a pharmacologic effect on proteins that interact with the imaging radioligands. To date, there is no compelling evidence favoring dopamine agonists over levodopa; either is an appropriate choice for initial treatment of PD.

PMID:
12580184
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center